Jul 17, 2019 / 07:00AM GMT
Operator
Ladies and gentlemen, welcome to the Sobi presentation of the Q2 results. I will now hand over to Guido Oelkers, CEO; Henrik Stenqvist, CFO; and Milan Zdravkovic, Head of R&D. Please go ahead.
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-CEO&President
Yes. Thank you so much. Good morning, everybody. It's really my pleasure to kick off our Q2 result presentation.
Let's go straight to Slide 3. The presenters, as mentioned -- forward-looking statements obviously as per usual. But the presenters today are myself, Henrik, CFO; and Milan, our Head of R&D. And I'm quite blessed to present what we believe are strong results.
So if we go straight into -- go to Page 4. So basically, when you look at it, what are the main thesis and that's the reason why we call it strong performance, sharper focus. We think that we are presenting here today very strong quarter results, financials as well. And what we also, let's say, show is that we strengthened our organization, particularly in the
Q2 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 17, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers